A detailed history of Eads & Heald Wealth Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Eads & Heald Wealth Management holds 1,198 shares of LLY stock, worth $953,212. This represents 0.5% of its overall portfolio holdings.

Number of Shares
1,198
Previous 1,296 7.56%
Holding current value
$953,212
Previous $1.17 Million 9.55%
% of portfolio
0.5%
Previous 0.57%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$772.14 - $960.02 $75,669 - $94,081
-98 Reduced 7.56%
1,198 $1.06 Million
Q2 2024

Jul 23, 2024

SELL
$724.87 - $909.04 $23,195 - $29,089
-32 Reduced 2.41%
1,296 $1.17 Million
Q1 2024

Apr 23, 2024

SELL
$592.2 - $792.28 $55,074 - $73,682
-93 Reduced 6.54%
1,328 $1.03 Million
Q4 2023

Jan 30, 2024

SELL
$525.19 - $619.13 $87,181 - $102,775
-166 Reduced 10.46%
1,421 $828,000
Q3 2023

Oct 27, 2023

SELL
$434.7 - $599.3 $102,589 - $141,434
-236 Reduced 12.95%
1,587 $852,000
Q2 2023

Jul 25, 2023

SELL
$350.74 - $468.98 $192,205 - $257,001
-548 Reduced 23.11%
1,823 $855,000
Q1 2023

Apr 21, 2023

SELL
$310.63 - $364.82 $11,803 - $13,863
-38 Reduced 1.58%
2,371 $814,000
Q4 2022

Jan 27, 2023

SELL
$321.55 - $374.67 $57,879 - $67,440
-180 Reduced 6.95%
2,409 $881,000
Q3 2022

Oct 27, 2022

SELL
$296.48 - $337.87 $115,034 - $131,093
-388 Reduced 13.03%
2,589 $837,000
Q2 2022

Jul 26, 2022

SELL
$278.73 - $327.27 $87,242 - $102,435
-313 Reduced 9.51%
2,977 $965,000
Q1 2022

Apr 27, 2022

SELL
$234.69 - $291.66 $72,284 - $89,831
-308 Reduced 8.56%
3,290 $942,000
Q4 2021

Jan 31, 2022

SELL
$224.85 - $279.04 $22,485 - $27,904
-100 Reduced 2.7%
3,598 $993,000
Q3 2021

Oct 27, 2021

SELL
$221.6 - $272.71 $81,992 - $100,902
-370 Reduced 9.1%
3,698 $854,000
Q2 2021

Jul 30, 2021

SELL
$180.55 - $233.54 $48,026 - $62,121
-266 Reduced 6.14%
4,068 $933,000
Q1 2021

Apr 29, 2021

SELL
$164.32 - $212.72 $70,657 - $91,469
-430 Reduced 9.03%
4,334 $809,000
Q4 2020

Feb 02, 2021

SELL
$130.46 - $172.63 $12,393 - $16,399
-95 Reduced 1.96%
4,764 $804,000
Q3 2020

Nov 02, 2020

BUY
$146.22 - $169.13 $5,117 - $5,919
35 Added 0.73%
4,859 $719,000
Q2 2020

Jul 29, 2020

BUY
$136.42 - $164.18 $4,638 - $5,582
34 Added 0.71%
4,824 $792,000
Q1 2020

May 01, 2020

SELL
$119.05 - $147.35 $36,786 - $45,531
-309 Reduced 6.06%
4,790 $664,000
Q4 2019

Jan 31, 2020

SELL
$106.92 - $132.43 $2,673 - $3,310
-25 Reduced 0.49%
5,099 $670,000
Q3 2019

Oct 31, 2019

BUY
$106.79 - $116.16 $5,125 - $5,575
48 Added 0.95%
5,124 $573,000
Q2 2019

Jul 30, 2019

SELL
$110.79 - $129.32 $35,785 - $41,770
-323 Reduced 5.98%
5,076 $0
Q1 2019

Apr 26, 2019

SELL
$111.31 - $131.02 $37,622 - $44,284
-338 Reduced 5.89%
5,399 $0
Q4 2018

Jan 31, 2019

SELL
$105.9 - $118.64 $29,652 - $33,219
-280 Reduced 4.65%
5,737 $663,000
Q3 2018

Oct 31, 2018

SELL
$85.86 - $107.31 $31,338 - $39,168
-365 Reduced 5.72%
6,017 $0
Q2 2018

Jul 27, 2018

SELL
$75.7 - $86.88 $44,814 - $51,432
-592 Reduced 8.49%
6,382 $0
Q1 2018

Apr 26, 2018

SELL
$74.21 - $87.6 $13,728 - $16,205
-185 Reduced 2.58%
6,974 $0
Q4 2017

Jan 31, 2018

SELL
$81.94 - $87.89 $1,638 - $1,757
-20 Reduced 0.28%
7,159 $0
Q3 2017

Oct 27, 2017

BUY
$77.07 - $85.54 $553,285 - $614,091
7,179
7,179 $0

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Eads & Heald Wealth Management Portfolio

Follow Eads & Heald Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eads & Heald Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Eads & Heald Wealth Management with notifications on news.